Article

Neuroprotective agent in sight?

A neuroprotective approach to the treatment of glaucoma is not imminent, but several promising approaches are under investigation.

Durham, NC-A neuroprotective approach to the treatment of glaucoma is not imminent, but several promising approaches are under investigation. Areas that hold the most possibility are targeting amyloid-beta, complement activation, and tumor necrosis factor (TNF)-alpha signaling, said Stuart J. McKinnon, MD, PhD.

"Will we have one in our lifetime? I hope so," he added. Dr. McKinnon reviewed several therapeutic strategies that have been successful using animal glaucoma models.

This finding suggests a possible relationship between the two diseases, Dr. McKinnon said. Altered metabolism of amyloid-beta and amyloid precursor protein (APP), which plays a central role in neuronal homeostasis, contributes to apoptosis of retinal ganglion cells (RGC) in glaucoma.

Two classes of drugs are FDA-approved to treat AD: acetylcholine esterase inhibitors (donepezil [Aricept, Pfizer/Eisai], rivastigmine [Exelon, Novartis] and galantamine [Razadyne, Ortho-McNeil-Janssen Pharmaceuticals]), and an N-methyl-D-aspartate receptor antagonist, memantine (Namenda, Forest Pharmaceuticals).

In a rat glaucoma model, galantamine was more neuroprotective than donepezil or memantine, Dr. McKinnon said, but memantine did not show any improvement in glaucoma in a large multicenter clinical trial.

Two anti-amyloid approaches that may be useful in the treatment of glaucoma are decreasing amyloid-beta production by secretase inhibition or interfering with amyloid-beta aggregation by using amyloid-beta vaccination. Another strategy that has demonstrated neuroprotection in a rat glaucoma model is the use of intravitreal antibodies to amyloid-beta, Congo red, and beta-secretase inhibitors, singly or in combination.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.